双靶联合紫杉醇加卡铂用于人表皮生长因子受体2阳性乳腺癌新辅助治疗的效果OA
Effect of Dual-Targeted Therapy Combined with Paclitaxel and Carboplatin as Neoadjuvant Treatment for Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
目的:探讨双靶联合紫杉醇加卡铂用于人表皮生长因子受体 2(HER2)阳性乳腺癌新辅助治疗的效果.方法:纳入2022年1月~2025 年7月本院收治的88例HER2阳性乳腺癌患者为研究对象,采用分层区组随机化方法分为对照组(主动退出1例,n=43)和研究组(主动退出 2 例,n=42).对照组接受双靶联合紫杉醇标准治疗,研究组在对照组基础上联合卡铂化疗,两组均持续治疗 6 个周期后观察疗效,包括影像学疗效评估、病理学完全缓解(pCR)率、肿瘤标志物[癌抗原15-3(CA15-3)、癌胚抗原(CEA)及组织多肽特异抗原(TPS)]及安全性.结果:治疗后,研究组客观缓解率(ORR)高于对照组(95.24%vs 79.07%,P<0.05);pCR率高于对照组(90.48%vs 72.09%,x2=4.699,P=0.030).两组CA15-3、CEA和TPS均降低,且研究组低于对照组(P<0.05).两组贫血、中性粒细胞减少、血小板减少、脱发、皮疹、恶心呕吐的不良反应等级分布情况比较均无统计学差异(P>0.05).结论:在本研究条件下,将双靶联合紫杉醇加卡铂应用于HER2阳性乳腺癌新辅助治疗中,可提高ORR及pCR率,降低肿瘤标志物水平.
Objective:To investigate the efficacy of dual-targeted therapy combined with paclitaxel and carboplatin as neoadjuvant treatment for human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods:A total of 88 patients with HER2-positive breast cancer admitted to our hospital from January 2022 to July 2025 were included.Stratified block randomization was used to assign patients to a control group(1 voluntary withdrawal;n=43)or a study group(2 voluntary withdrawals;n=42).The control group received standard treatment with dual-targeted therapy plus paclitaxel,whereas the study group received the same regimen with carboplatin added.Both groups were treated for 6 cycles.Efficacy was evaluated on the basis of radiologic response,the pathological complete response(pCR)rate,tumor marker levels[cancer antigen 15-3(CA15-3),carcinoembryonic antigen(CEA),and tissue polypeptide-specific antigen(TPS)],and safety.Results:After treatment,the objective response rate(ORR)was higher in the study group than in the control group(95.24%vs 79.07%,P<0.05),as was the pCR rate(90.48%vs 72.09%,x2=4.699,P=0.030).CA15-3,CEA,and TPS levels decreased in both groups and were lower in the study group than in the control group(P<0.05).No statistically significant between-group differences were observed in the grade distributions of anemia,neutropenia,thrombocytopenia,alopecia,rash,or nausea and vomiting(P>0.05).Conclusion:Under the conditions of this study,dual-targeted therapy combined with paclitaxel and carboplatin as neoadjuvant treatment for HER2-positive breast cancer increased the ORR and pCR rate and reduced tumor marker levels.
谢毅;张德智;刘旭辉;韩志伟;赵玉鹏;杨鲁丽
义马煤业集团股份有限公司总医院普通外科,义马 472300义马煤业集团股份有限公司总医院普通外科,义马 472300义马煤业集团股份有限公司总医院普通外科,义马 472300义马煤业集团股份有限公司总医院普通外科,义马 472300义马煤业集团股份有限公司总医院普通外科,义马 472300义马煤业集团股份有限公司总医院普通外科,义马 472300
医药卫生
乳腺癌人表皮生长因子受体2阳性曲妥珠单抗帕妥珠单抗紫杉醇卡铂
breast cancerhuman epidermal growth factor receptor 2-positivetrastuzumabpertuzumabpaclitaxelcarboplatin
《中国合理用药探索》 2026 (8)
35-42,8
评论